www.fdanews.com/articles/200107-intersect-ent-makes-executive-leadership-changes
Intersect ENT Makes Executive Leadership Changes
November 20, 2020
Menlo Park, Calif.-based Intersect ENT, a developer of drug-delivery devices for the ear, nose and throat, has named Patrick Broderick as its new general counsel.
A former head of the legal department of distribution giant McKesson, Broderick most recently served as general counsel and chief compliance officer at Grail, an oncology test developer.
Intersect ENT’s core technology is a bioabsorbable drug-release system for the localized release of steroids for the treatment of sinusitis.